openPR Logo
Press release

Antisense Oligonucleotides Market to Record an Exponential CAGR by 2027

05-14-2018 08:43 AM CET | Advertising, Media Consulting, Marketing Research

Press release from: Future Market Insights

Antisense Oligonucleotides Market to Record an Exponential

Antisense oligonucleotides (ASOs) are 15–25 nt oligonucleotides designed to tie complementary RNA targets for the degradation. They are synthesized so that they can be used to block disease processes by altering the synthesis of a specific protein. ASOs offers promising treatment options for a range of medical disorders. They facilitate the development of therapeutics affecting protein targets which cannot be treated with protein therapeutics. They can target a particular malfunctioning gene, interfere with RNA function at cellular level, and can also be silenced or modulated. It allows modifications in immune system that facilitates treatment of a wide range of autoimmune disorders – that cannot be treated with available drugs. It is easy to scale up the commercial scale GMP production of these oligonucleotides compared to other biologic therapies. Moreover, the side effects of antisense oligonucleotides are minimal and can be controlled with ease as compared to other class of drugs.

Request For TOC @ https://www.futuremarketinsights.com/toc/rep-gb-5377

Though, the antisense oligonucleotides market has witnessed four FDA approvals [fomivirsen (Vitravene) approved in 1998 – which was discontinued due to low demand; pegaptanib (Macugen) in 2004; mipomersen (Kynamro) in 2013; and eteplirsen (Exondys 51) in 2016). However, this market is yet to achieve recognition as a valuable drug category like biologics, small molecules, and gene and cell therapy. However, in December 2016, this was projected to change with the approval of nusinersen (Spinraza) for treating spinal muscular atrophy (SMA), which is one of the most common genetic cause for infant mortality with no approved treatments. Spinraza has shown unprecedented results for the treatment of SMA in clinical trials.

Antisense Oligonucleotides Market: Drivers and Restraints

Strong pipeline of antisense oligonucleotides and increased focused on large number of product approvals and commercialization are some of the primary factors driving the growth of the global antisense oligonucleotides market. Moreover, significant advances in the field of antisense oligonucleotides at a therapeutic or clinical level is further contributing to the growth of the global antisense oligonucleotides market. However, the global antisense oligonucleotides market is grappling with numerous challenges related to diversity of oligonucleotides, delivery, and regulatory complexity. Despite several advancements at clinical levels, the delivering of active oligonucleotide to the actual site within target cells is still one of the major challenges hindering the growth of the global antisense oligonucleotides market. In addition to this, developing a new set of unique regulatory guidelines is another challenge limiting the growth of the global antisense oligonucleotides market.

Antisense Oligonucleotides Market: Segmentation

Tentatively, the global antisense oligonucleotides market has been segmented on the basis of drug, indication, end user and geography.

Based on drug, the global antisense oligonucleotides market is segmented as below:

Approved Drugs
Pegaptanib
Mipomersen
Eteplirsen
Pipeline Analysis
Based on indication, the global antisense oligonucleotides market is segmented as below:

Ocular Diseases
Cancer
Diabetes
Amyotrophic Lateral Sclerosis (ALS)
Duchenne Muscular Dystrophy
Spinal Muscular Atrophy
Others
Based on application, the global antisense oligonucleotides market is segmented as below:

Basic Research
Genomics
Target Validation
Drug Discovery
Antisense Oligonucleotides Market: Overview

Although the development of oligonucleotide therapeutics commenced in 1970s, FDA has approved only four oligonucleotide drugs (of which fomivirsen was discontinued) nearly a half century later. However, the filed is gaining momentum and is set to offer promising growth opportunities with a strong pipeline of 135 oligonucleotides in various stages of clinical trials. Even when the market performance of antisense oligonucleotides is not predictable as like other segments of the industry, the future looks very promising primarily reflected by the leadings players in the market and the amount of research and development investments.

Antisense Oligonucleotides Market: Regional Outlook

Geographically, the global antisense oligonucleotides market is segmented into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. North America clearly dominates the global antisense oligonucleotides market due to a strong product pipeline and increasing number of FDA approvals in the region.

Request For Sample @https://www.futuremarketinsights.com/askus/rep-gb-5377

Antisense Oligonucleotides Market: Key Players

Some of the players identified in the global antisense oligonucleotides market include Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Biogen, Alnylam Pharmaceuticals, Inc., Antisense Therapeutics Limited, Isarna Therapeutics GmbH, Arrowhead Pharmaceuticals, Inc., Atlantic Pharmaceuticals, Inc., Enzon Pharmaceuticals, Inc., Bio-Path Holdings, Inc., Gene Signal International SA, GlaxoSmithKline plc, Geron Corporation, Gradalis, ICO Therapeutics, Aptose Biosciences, Marina Biotech, miRagen Therapeutics, Inc., Synlogic, Inc., OncoGenex Pharmaceuticals Inc., Pharmaxis Ltd, Regulus Therapeutics Inc., Rexahn Pharmaceuticals, Inc., and RXi Pharmaceuticals, among others.

ABOUT US:
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature.
FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

CONTACT:
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website: http://www.futuremarketinsights.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antisense Oligonucleotides Market to Record an Exponential CAGR by 2027 here

News-ID: 1048237 • Views: …

More Releases from Future Market Insights

Global Lithium Ion Battery Separator Market Projected to Reach US$ 3,256.7 Million by 2032
Global Lithium Ion Battery Separator Market Projected to Reach US$ 3,256.7 Milli …
The lithium-ion battery separator is a critical component in lithium-ion batteries, responsible for preventing short circuits and ensuring safe and efficient battery performance. It acts as a physical barrier between the positive and negative electrodes, allowing lithium ions to pass through while blocking the flow of electrons. With advancements in separator technology, these separators play a key role in enhancing battery capacity, cycle life, and overall safety in various applications,…
Industrial Drums Market on a Trajectory to Reach US$ 17.6 Billion by 2027, Bolstered by a Robust 7.1% CAGR from 2022
Industrial Drums Market on a Trajectory to Reach US$ 17.6 Billion by 2027, Bolst …
The Industrial Drums Market is experiencing a steady and promising trajectory, with an estimated value of US$ 12.5 billion in 2022, projected to escalate to US$ 17.6 billion by 2027 at a commendable Compound Annual Growth Rate (CAGR) of 7.1%. This growth is substantiated by a 6.6% CAGR in volume during 2022-27, as per Future Market Insights. Anticipated to expand 1.5 times within this period, the market presents alluring prospects for industry…
Supermarkets, Convenience Stores, and Eco-friendly Choices Fuel the Expansion of the Metal Cans Industry, Catering to Health-conscious and Environmentally-aware Consumers
Supermarkets, Convenience Stores, and Eco-friendly Choices Fuel the Expansion of …
The metal cans market is predicted to grow at a CAGR of 5% over the forecast period, according to research by Future Market Insights. The industry's estimated value is expected to increase from US$ 56 Bn in 2023 to US$ 91.1 Bn by 2033. The market for metal cans has been driven by the heightened demand for the product in food and beverages industry. Metal cans helps prolong shelf-life of perishable…
Folding IBCs Market Poised for Growth: Expected to Reach US$ 528 Million by 2027 with a 4.8% CAGR
Folding IBCs Market Poised for Growth: Expected to Reach US$ 528 Million by 2027 …
The folding intermediate bulk containers (IBCs) market is on a growth trajectory, with an estimated value of US$ 418 million in 2022, projected to reach US$ 528 million by 2027, showcasing a Compound Annual Growth Rate (CAGR) of 4.8%. Remarkably, the China folding IBCs market defied initial pandemic-related skepticism and is anticipated to grow by 6.9% year on year in 2022. Despite global challenges, China's folding IBCs market is poised to contribute…

All 5 Releases


More Releases for Antisense

Antisense and RNAi Therapeutics Market Report Up to 2031
Antisense and RNAi Therapeutics Market– our new study reveals trends, R&D progress, and predicted revenues Where is the Antisense and RNAi Therapeutics market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there. Download Exclusive Sample of Report @ https://www.visiongain.com/report/antisense-and-rnai-therapeutics-market/#download_sampe_div Discover how to stay ahead Our Antisense and RNAi Therapeutics report…
Global Antisense and RNAi Therapeutics Market Analysis (2020-2025)
Global Info Research offers a latest published report on Antisense and RNAi Therapeutics Analysis and Forecast 2020-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Antisense and RNAi Therapeutics Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. Click to view the full report…
Antisense Therapy Market: Competitive Dynamics & Global Outlook 2020-2025
This report also researches and evaluates the impact of Covid-19 outbreak on the Antisense Therapy industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Antisense Therapy and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.). Global Antisense Therapy Market Overview: GLOBAL INFO RESEARCH has evaluated the global Antisense Therapy market in its latest research report. The research report, titled [Global Antisense Therapy…
Antisense Therapy Market to Witness Robust Expansion by 2025
LP INFORMATION recently released a research report on the Antisense Therapy market analysis, which studies the Antisense Therapy's industry coverage, current market competitive status, and market outlook and forecast by 2025. Global "Antisense Therapy Market 2020-2025" Research Report categorizes the global Antisense Therapy market by key players, product type, applications and regions,etc. The report also covers the latest industry data, key players analysis, market share, growth…
Antisense Oligonucleotides Market Opportunity Analysis, 2026
Antisense oligonucleotides are short, single stranded RNA or DNA molecules. Antisense oligonucleotides do not modulate the activity of already formed proteins, however they act before proteins are produced at the level of messenger RNA in the cell. Antisense oligonucleotides is used in treatment of oncology, Central nervous system therapeutics, inflammation therapeutics, diabetes, asthma, hair loss, etc. Antisense oligonucleotides is also used in genomics. Some examples of antisense nucleotides are fomivirsen…
Antisense Oligonucleotides Market Report 2017 – 2027: By Application
Antisense oligonucleotides (ASOs) are 15–25 nt oligonucleotides designed to tie complementary RNA targets for the degradation. They are synthesized so that they can be used to block disease processes by altering the synthesis of a specific protein. ASOs offers promising treatment options for a range of medical disorders. They facilitate the development of therapeutics affecting protein targets which cannot be treated with protein therapeutics. They can target a particular malfunctioning…